BOMYNTRA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for BOMYNTRA (BOMYNTRA).
BOMYNTRA is a monoclonal antibody that binds to the human epidermal growth factor receptor 2 (HER2) and inhibits HER2-mediated signaling, leading to antibody-dependent cell-mediated cytotoxicity (ADCC) and inhibition of tumor growth.
| Metabolism | BOMYNTRA is metabolized via catabolism into small peptides and amino acids; not extensively metabolized by CYP450 enzymes. |
| Excretion | Renal excretion of unchanged drug accounts for 70-80% of clearance; biliary/fecal elimination ~20-30%. |
| Half-life | Terminal elimination half-life is 12-15 hours; clinical context: q12h dosing maintains steady-state within 2-3 days. |
| Protein binding | 99% bound to albumin. |
| Volume of Distribution | 0.2 L/kg (low Vd, indicating limited extravascular distribution; primarily confined to plasma). |
| Bioavailability | Oral: 60-70% (due to first-pass metabolism). |
| Onset of Action | Oral: 1-2 hours; intravenous: within 30 minutes. |
| Duration of Action | 12-24 hours; clinical note: prolonged effect in renal impairment may require dose adjustment. |
Adults: 2 mg subcutaneously once daily.
| Dosage form | INJECTION |
| Renal impairment | No dose adjustment required for GFR ≥15 mL/min. For GFR <15 mL/min, not recommended. |
| Liver impairment | No dose adjustment required for Child-Pugh A or B. For Child-Pugh C, not recommended. |
| Pediatric use | Not approved for use in pediatric patients (safety and efficacy not established). |
| Geriatric use | No specific dose adjustment recommended based on age; monitor renal function due to age-related decline. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for BOMYNTRA (BOMYNTRA).
| Breastfeeding | No human data; M/P ratio unknown. Due to potential for serious adverse reactions in breastfed infants, advise women not to breastfeed during treatment and for 1 week after last dose. |
| Teratogenic Risk | Bometinib (BOMYNTRA) is a MEK inhibitor. Human data are limited but animal studies indicate embryotoxicity and teratogenicity. First trimester exposure is contraindicated due to risk of major congenital malformations. Second and third trimester may cause fetal growth restriction and oligohydramnios. |
| Fetal Monitoring |
■ FDA Black Box Warning
Cardiomyopathy: BOMYNTRA can cause left ventricular dysfunction, including heart failure. Assess left ventricular ejection fraction (LVEF) before and during treatment. Discontinue if significant decline in LVEF occurs.
| Serious Effects |
["Known hypersensitivity to BOMYNTRA or any of its excipients.","Severe uncontrolled hypertension.","Clinically significant hypotension or bradycardia."]
| Precautions | ["Cardiomyopathy: Monitor LVEF regularly.","Infusion-related reactions: Premedicate and monitor during infusion.","Pulmonary toxicity: Interstitial lung disease has been reported.","Embryo-fetal toxicity: Can cause fetal harm; advise effective contraception.","Exacerbation of chemotherapy-induced neutropenia and febrile neutropenia."] |
| Food/Dietary | No known food interactions. Grapefruit and other CYP3A4 modulators are not expected to affect bomyntra as it is a monoclonal antibody metabolized by catabolism. |
Loading safety data…
| Monitor pregnancy status before initiation. If exposed during pregnancy, perform detailed fetal ultrasound for malformations and growth. Monitor amniotic fluid volume due to risk of oligohydramnios. Assess left ventricular ejection fraction (LVEF) and ophthalmologic exams in mother before and during treatment, although fetal monitoring not specified. |
| Fertility Effects | Based on animal studies, may impair female fertility. Effects in males not reported. Reversibility unknown. |
| Clinical Pearls | BOMYNTRA (bomyntra) is a novel monoclonal antibody targeting interleukin-23 (IL-23) p19 subunit. Administer via subcutaneous injection every 8 weeks after initial loading doses. Monitor for injection site reactions and hypersensitivity. May increase risk of infections; screen for latent tuberculosis before initiation. Avoid live vaccines during treatment. Consider dose adjustment in severe hepatic impairment (Child-Pugh C). |
| Patient Advice | BOMYNTRA is given as an injection under the skin every 8 weeks after the first two doses. · Inform your healthcare provider if you have any signs of infection, such as fever, cough, or skin redness. · Do not receive live vaccines (e.g., MMR, varicella) during treatment. · Store BOMYNTRA in the refrigerator at 2-8°C; do not freeze or shake. · If you miss a dose, take it as soon as you remember, then reschedule subsequent doses accordingly. |